A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Long-term Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Long-term Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.
Inclusion Criteria:
Exclusion Criteria:
Birmingham, Alabama 35294, United States
Colorado Springs, Colorado 80906, United States
Clearwater, Florida 33756, United States
Jacksonville, Florida 32216, United States
Jacksonville, Florida 32216, United States
Jacksonville, Florida 32216, United States
Jacksonville, Florida 32216, United States
Iowa City, Iowa 52242, United States
New Brunswick, New Jersey 08901, United States
Cincinnati, Ohio 45219, United States
Cambridge, Ontario N1R 7R1, Canada
MedellÃn, Antioquia 50031, Colombia
Barranquilla, Atlántico 80020, Colombia
Bogota, Cundinamarca 110221, Colombia
Bogota, Cundinamarca, Colombia
Guadalajara, Jalisco 44600, Mexico
Cuernavaca, Morelos 62270, Mexico
San Luis Potosà City, San Luis Potosà 78200, Mexico
Naucalpan, State of Mexico 35510, Mexico
Brasov, 500283, Romania
Kemerovo, 650002, Russia
Saint Petersburg, 197706, Russia
Saint Petersburg, 198205, Russia
Antrim, Northern Ireland BT41 3AE, United Kingdom
Portadown, Northern Ireland BT63 5QQ, United Kingdom
Hexham, Northumberland NE46 1QJ, United Kingdom
Bradford-on-Avon, Wiltshire BA15 1DQ, United Kingdom